Patent

GlycoNex Inc. has been committed to developing advanced technology and building up intellectual property. In addition to the patent license from the Biomembrane Institute (TBI), exceptional research accomplishments on glycosphingolipids/antibody have been made in recent years. The global intellectual property protection has been established through patent systems such as PCT, EPC and USPTO.

 

 

Country Patent Number Patent Title
Canada 1339622 Oncofetal Fibronectin Epitope
US 6083929 Extended Type 1 chain glycosphingolipids as tumor-associated antigens 
US 6294523 Extended Type 1 chain glycosphingolipids as tumor-associated antigens
Australia 2000260652 Extended Type 1 chain glycosphingolipids as tumor-associated antigens
Singapore 94177 (Publication number) Extended Type 1 chain glycosphingolipids as tumor-associated antigens
Taiwan I265811(Application number: 089113225) Extended Type 1 chain Glycosphingolipids as tumor-associated antigens
Korea 0666238 Extended Type 1 chain Glycosphingolipids as tumor-associated antigens
China 00819788.1 Extended Type 1 chain glycosphingolipids as tumor-associated antigens
US 8163497 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof and Use
South Africa 2011/01547 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof and Use
Russia 2478648 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof and Use
New Zealand 591488 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof and Use
Australia 2008361352 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof and Use
China ZL 2008 8 0131006. 5 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof and Use
Taiwan I 433684 Anti-Extended Type I Glycosphingolipid Antibody, Derivatives Thereof and Use